Financière de Tubize SAの売上総利益
Financière de Tubize SAの売上総利益 は何ですか。
Financière de Tubize SAの売上総利益 は-22,250.00%です。
売上総利益 の定義は何ですか。
売上総利益は、売上と商品の売上原価との差を収益で除してパーセンテージで表したものです。
Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.
EURONEXTのセクタHealth Careにおける売上総利益 の企業と比べるFinancière de Tubize SA
Financière de Tubize SAは何をしますか。
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Financière de Tubize SAと類似の売上総利益
- Magnis Resourcesの売上総利益 は-45,793.10%です。
- Pure Mineralsの売上総利益 は-44,700.00%です。
- Condor Technologies NVの売上総利益 は-41,600.00%です。
- CytoDynの売上総利益 は-27,547.74%です。
- Aqua Metals Incの売上総利益 は-25,028.00%です。
- Alpha HPAの売上総利益 は-22,812.50%です。
- Financière de Tubize SAの売上総利益 は-22,250.00%です。
- Hannansの売上総利益 は-20,600.00%です。
- Neovacs S.Aの売上総利益 は-20,146.52%です。
- LQwD FinTechの売上総利益 は-20,000.00%です。
- Interlapse Technologiesの売上総利益 は-20,000.00%です。
- GOLO Mobileの売上総利益 は-19,675.47%です。
- Coastal Greenlandの売上総利益 は-18,994.50%です。